Global health challenges are not easy to overcome. In resource-limited settings and emerging markets, these challenges call for medicines and other products designed to address specific needs. Our Research & Development team works collaboratively to develop fully integrated medical solutions for regions where the need is great, but resources are few.
Currently, around 75 percent of MDR-TB cases are left untreated and mortality and loss to follow-up rates are high. Through public-private partnerships in research and development, differentiated pricing, and collaborations around responsible use and distribution, we are working to address this disease.
We are exploring innovative applications of our HIV medicines to improve treatment and prevention outcomes in hard‐to‐reach areas by finding ways to reduce the frequency of dosing. We’re also working in collaboration with non-profit product development partners to research new pathways to prevent HIV infection through injectable formulations and microbicidal rings.
Janssen is playing a leading role in the Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF) study – a multi-center, multi-country, open-label study underway at 23 sites in five sub-Saharan African countries and one country in Asia-Pacific. SALIF is exploring one of our HIV medicines as a potential “switch” option once a viral load of <50 copies/mL is reached.
In 2012, Johnson & Johnson signed the London Declaration on Neglected Tropical Diseases, a multilateral partnership to eliminate or control 10 NTDs by the end of the decade. As part of this commitment, Janssen is working to enhance the company’s efforts in innovation and access toward neglected diseases.